Skip to content
Neuronal Paraneoplastic Panel: An Advanced Test for Investigating Cancer-Associated Neurological Disorders
Health & Diagnostics

Neuronal Paraneoplastic Panel: An Advanced Test for Investigating Cancer-Associated Neurological Disorders

August 23, 2026

Life Quest Clinical Lab now offers the Neuronal Paraneoplastic Panel (12 Antigen) — a specialised immunological test to help evaluate neurological disorders that may be associated with an underlying malignancy.

Life Quest Clinical Lab is pleased to introduce the Neuronal Paraneoplastic Panel (12 Antigen), an advanced immunological investigation designed to support the evaluation of certain neurological disorders that may be associated with an underlying malignancy.

Some neurological symptoms can develop as a result of the body's immune response to cancer. These conditions are known as paraneoplastic neurological disorders, in which the immune system reacts against components of the nervous system in association with an underlying cancer.

Neurological manifestations may sometimes occur before an underlying malignancy is identified — making appropriate laboratory evaluation an important component of the clinical investigation in selected patients.

What Are Paraneoplastic Neurological Disorders?

Paraneoplastic autoimmune neurological disorders reflect humoral and cellular immune responses to cancer. Patients with detectable neuronal autoantibodies may present with a variety of neurological manifestations, including:

  • Encephalopathy
  • Cerebellar ataxia
  • Radiculopathy
  • Myelopathy
  • Neuromuscular transmission disorders

These neurological presentations can sometimes be subacute and may have an unclear cause at the initial stage of investigation.

Why Is the Neuronal Paraneoplastic Panel Important?

The presence of specific neuronal antibodies can provide valuable information when clinicians are investigating a neurological disorder in which an autoimmune or paraneoplastic cause is suspected.

The 12-antigen panel may be particularly relevant in selected patients with:

  • A previous history of cancer
  • Family history of cancer
  • History of smoking
  • Significant environmental exposure to carcinogens
  • New or unexplained subacute neurological symptoms

When Can the Test Be Considered?

1. Unexplained Neurological Symptoms

The panel can assist in the evaluation of patients who develop subacute neurological disorders without an established cause, particularly when an underlying cancer is a clinical concern.

2. Neurological Symptoms in Patients With Cancer

Some neurological symptoms may appear during or following cancer therapy and may not be explained by metastatic disease. In such circumstances, paraneoplastic autoimmune evaluation may form part of the diagnostic work-up.

3. Investigation of Occult Malignancy

In selected patients, a positive paraneoplastic antibody finding may prompt clinicians to investigate for an underlying or occult malignancy that has not yet been identified.

4. Differentiating Neurological Causes

The test may also support the differentiation of autoimmune neuropathies from neurotoxic effects associated with chemotherapy, where the clinical presentation may otherwise be difficult to distinguish.

5. Monitoring During Cancer Management

In patients who are already known to be seropositive, the investigation may be used as part of monitoring the immune response during cancer therapy and may also assist in detecting early evidence of recurrence.

An Important Part of a Multidisciplinary Evaluation

Paraneoplastic antibody testing is most useful when interpreted together with the patient's clinical history, neurological examination, imaging findings, cancer history and risk factors, and other relevant investigations. A laboratory result should always be interpreted by the treating physician within the overall clinical context.

Life Quest Clinical Lab: Expanding Access to Specialised Diagnostics

At Life Quest Clinical Lab, we are continuously working to expand access to specialised and advanced laboratory investigations in Nepal. The introduction of the Neuronal Paraneoplastic Panel (12 Antigen) reflects our commitment to providing healthcare professionals with advanced diagnostic options that can support complex clinical decision-making.

The Neuronal Paraneoplastic Panel (12 Antigen) is now available through Life Quest Clinical Lab. For test availability, sample requirements, turnaround time, and clinical consultation, healthcare professionals are encouraged to contact Life Quest Clinical Lab.